Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. (3-iodo-(131i)benzyl)guanidine
2. 123i Labeled 3-iodobenzylguanidine
3. 125i Labeled 3-iodobenzylguanidine
4. 3 Iodobenzylguanidine
5. 3 Iodobenzylguanidine, 123i Labeled
6. 3 Iodobenzylguanidine, 125i Labeled
7. 3-iodobenzylguanidine
8. 3-iodobenzylguanidine, 123i Labeled
9. 3-iodobenzylguanidine, 125i Labeled
10. Iobenguane
11. Iobenguane (131i)
12. M Iodobenzylguanidine
13. M-iodobenzylguanidine
14. Meta Iodobenzylguanidine
15. Meta-iodobenzylguanidine
16. Mibg
1. 87862-25-7
2. Mibg
3. Iobenguane Sulphate
4. M-iodobenzylguanidine Hemisulfate
5. M-iodobenzyl Guanidine Sulfate
6. 1-(3-iodobenzyl)guanidine Hemisulfate
7. Mibg (sulfate)
8. 3-iodobenzyl-guanidine Sulfate
9. M-iodobenzyl Guanidine Sulphate
10. 3-iodobenzyl-guanidine Sulphate
11. Iobenguane (sulfate)
12. Guanidine, N-((3-iodophenyl)methyl)-, Sulfate (2:1)
13. M-idobenzyl Guanidine Sulfate [vandf]
14. Guanidine, [(3-iodophenyl)methyl]-, Sulfate (2:1)
15. M-iodobenzylguanidine Hemisulfate Salt
16. Mibg Hemisulfate
17. Ncgc00094011-01
18. S8i0922465
19. Dsstox_cid_25773
20. Dsstox_rid_81115
21. Dsstox_gsid_45773
22. 3-iodobenzylguanidine Hemisulfate
23. Cas-87862-25-7
24. Ncgc00015572-04
25. Eu-0100644
26. 1-(3-iodobenzyl)guanidine Hcl
27. Chembl1374843
28. 3-iodobenzylguanidine Hemisulphate
29. 3-iodobenzyl-guanidine Hemisulfate
30. Hms3262a09
31. Unii-s8i0922465
32. Tox21_111237
33. Tox21_113518
34. Tox21_500644
35. 1-(3-iodobenzyl)guanidinehemisulfate
36. Akos015996512
37. Meta-iodobenzylguanidine Sulfate
38. Ccg-221948
39. Lp00644
40. Ncgc00261329-01
41. Bs-45793
42. E74924
43. I 9890
44. 2-[(3-iodophenyl)methyl]guanidine; Sulfuric Acid
45. A839961
46. 2-[(3-iodanylphenyl)methyl]guanidine; Sulfuric Acid
47. Q27289056
48. M-iodobenzylguanidine Hemisulfate Salt, >=98% (hplc And Tlc)
49. 3-iodobenzyl-guanidine Hemisulfate 103346-16-3 80663-96-3
50. Iobenguane Sulfate, European Pharmacopoeia (ep) Reference Standard
51. 80663-96-3
Molecular Weight | 648.3 g/mol |
---|---|
Molecular Formula | C16H22I2N6O4S |
Hydrogen Bond Donor Count | 6 |
Hydrogen Bond Acceptor Count | 6 |
Rotatable Bond Count | 4 |
Exact Mass | 647.95127 g/mol |
Monoisotopic Mass | 647.95127 g/mol |
Topological Polar Surface Area | 212 Ų |
Heavy Atom Count | 29 |
Formal Charge | 0 |
Complexity | 247 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 3 |
Antineoplastic Agents
Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)
Enzyme Inhibitors
Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)
Radiopharmaceuticals
Compounds that are used in medicine as sources of radiation for radiotherapy and for diagnostic purposes. They have numerous uses in research and industry. (Martindale, The Extra Pharmacopoeia, 30th ed, p1161) (See all compounds classified as Radiopharmaceuticals.)
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 21543
Submission : 2008-04-18
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 21543
Submission : 2008-04-18
Status : Active
Type : II
22 Mar 2021
// BUSINESSWIRE
https://www.businesswire.com/news/home/20210322005101/en/Lantheus-Announces-Presentation-Featuring-AZEDRA%C2%AE-iobenguane-I-131-at-ENDO-2021#:~:text=Business%20Wire-,Lantheus%20Announces%20Presentation%20Featuring%20AZEDRA%C2%AE,I%20131)%20at%20ENDO%202021&text=NORTH%20BILLERICA%2C%20Mass.%2D%2D(BUSINESS,WIRE)%2D%2DLantheus%20Holdings%2C%20Inc.&text=%E2%80%9CAZEDRA%20is%20the%20first%20and,Chief%20Medical%20Officer%20of%20Lantheus.
03 Oct 2019
// Conor Hale FIERCE BIOTECH
https://www.fiercebiotech.com/medtech/lantheus-to-buy-progenics-to-chase-both-cancer-imaging-diagnostics-and-therapeutics
31 Jul 2018
// Manas Mishra REUTERS
https://www.reuters.com/article/us-progenics-pharm-fda/fda-approves-progenics-treatment-for-rare-adrenal-gland-tumors-idUSKBN1KK2C2
31 Jul 2018
// Mark Terry BIOSPACE
https://www.biospace.com/article/fda-approves-progenics-pharma-s-azedra-for-ultra-rare-cancers/
31 Jul 2018
// GLOBENEWSWIRE
https://globenewswire.com/news-release/2018/07/31/1544259/0/en/Progenics-Pharmaceuticals-Announces-FDA-Approval-for-AZEDRA-iobenguane-I-131-to-Treat-Unresectable-Locally-Advanced-or-Metastatic-Pheochromocytoma-or-Paraganglioma.html
31 Jul 2018
// Joy Persaud PHARMAPHORUM
https://pharmaphorum.com/cancer/fda-approves-first-drug-to-treat-rare-adrenal-cancer/
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?